

Research

Open Access

## Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD

Carol A Colton\*<sup>1</sup>, Ryan T Mott<sup>1</sup>, Hayley Sharpe<sup>2</sup>, Qing Xu<sup>1</sup>, William E Van Nostrand<sup>3</sup> and Michael P Vitek<sup>1</sup>

Address: <sup>1</sup>Duke University Medical Center, Division of Neurology, Durham, NC 27710, USA, <sup>2</sup>University of Bath, Department of Biology and Biochemistry, Clavertone Down, Bath, BA2 7AY, UK and <sup>3</sup>Department of Medicine, Stony Brook University, Stony Brook NY 11794, USA

Email: Carol A Colton\* - [glia01@aol.com](mailto:glia01@aol.com); Ryan T Mott - [mott0003@mc.duke.edu](mailto:mott0003@mc.duke.edu); Hayley Sharpe - [bs2hjs@bath.ac.uk](mailto:bs2hjs@bath.ac.uk); Qing Xu - [qxu001@duke.edu](mailto:qxu001@duke.edu); William E Van Nostrand - [wvannst@notes.cc.sunysb.edu](mailto:wvannst@notes.cc.sunysb.edu); Michael P Vitek - [vitek001@mc.duke.edu](mailto:vitek001@mc.duke.edu)

\* Corresponding author

Published: 27 September 2006

Received: 25 July 2006

*Journal of Neuroinflammation* 2006, 3:27 doi:10.1186/1742-2094-3-27

Accepted: 27 September 2006

This article is available from: <http://www.jneuroinflammation.com/content/3/1/27>

© 2006 Colton et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Microglia are associated with neuritic plaques in Alzheimer disease (AD) and serve as a primary component of the innate immune response in the brain. Neuritic plaques are fibrous deposits composed of the amyloid beta-peptide fragments (A $\beta$ ) of the amyloid precursor protein (APP). Numerous studies have shown that the immune cells in the vicinity of amyloid deposits in AD express mRNA and proteins for pro-inflammatory cytokines, leading to the hypothesis that microglia demonstrate classical (Th-1) immune activation in AD. Nonetheless, the complex role of microglial activation has yet to be fully explored since recent studies show that peripheral macrophages enter an "alternative" activation state.

**Methods:** To study alternative activation of microglia, we used quantitative RT-PCR to identify genes associated with alternative activation in microglia, including arginase I (*AGI*), mannose receptor (*MRC1*), found in inflammatory zone 1 (*FIZZ1*), and chitinase 3-like 3 (*YMI*).

**Results:** Our findings confirmed that treatment of microglia with anti-inflammatory cytokines such as IL-4 and IL-13 induces a gene profile typical of alternative activation similar to that previously observed in peripheral macrophages. We then used this gene expression profile to examine two mouse models of AD, the APP<sup>sw</sup> (Tg-2576) and Tg-SwDI, models for amyloid deposition and for cerebral amyloid angiopathy (CAA) respectively. *AGI*, *MRC1* and *YMI* mRNA levels were significantly increased in the Tg-2576 mouse brains compared to age-matched controls while *TNF $\alpha$*  and *NOS2* mRNA levels, genes commonly associated with classical activation, increased or did not change, respectively. Only *TNF $\alpha$*  mRNA increased in the Tg-SwDI mouse brain. Alternative activation genes were also identified in brain samples from individuals with AD and were compared to age-matched control individuals. In AD brain, mRNAs for *TNF $\alpha$* , *AGI*, *MRC1* and the chitinase-3 like 1 and 2 genes (*CHI3L1*; *CHI3L2*) were significantly increased while *NOS2* and *IL-1 $\beta$*  mRNAs were unchanged.

**Conclusion:** Immune cells within the brain display gene profiles that suggest heterogeneous, functional phenotypes that range from a pro-inflammatory, classical activation state to an alternative activation state involved in repair and extracellular matrix remodeling. Our data suggest that innate immune cells in AD may exhibit a hybrid activation state that includes characteristics of classical and alternative activation.

## Background

As part of the innate immune system, macrophages rapidly respond to a large variety of pathological molecular pattern stimuli (PAMPS) such as bacterial coat and viral proteins [1,2]. The programmed response to acute stimuli includes the induction of a specific gene profile and the subsequent production of multiple cytoactive factors such as TNF $\alpha$ , NO and IL-1 that protect against tissue invaders. In peripheral macrophages, this first phase of an innate immune response has been described as classical immune activation [1-3]. "Classical activation" is also characterized by the involvement of Th-1 cytokines such as interferon- $\gamma$  (IFN- $\gamma$ ), a "master" cytokine that orchestrates the coordinated induction and production of the "killing" phase [4-6]. However, the gene profile of macrophages can change, shutting down the production of pro-inflammatory cytokines and increasing the production of factors that participate in tissue repair and wound healing [6]. Anti-inflammatory, Th-2 cytokines such as IL-10 and TGF $\beta$  are associated with broad ranging and potent inhibition of pro-inflammatory activity while other Th-2 cytokines such as IL-4 and IL-13 serve to antagonize IFN- $\gamma$ , are anti-parasitic, mediate allergic responses and induce tissue matrix reconstruction [6,7]. IL-4 and IL-13 mediated gene induction has been specifically termed alternative activation and includes genes that produce arginase I (*AG1*), mannose receptors (*MRC1*) and genes associated with tissue remodeling such as Found in Inflammatory Zone 1 (*FIZZ1*) and chitinase 3-like 3 (*YM1*) [8-11].

The induction of the genes characteristic of alternative activation during an immune response provides an anti-inflammatory balance to an acute, pro-inflammatory response. Consequently, alternatively activated macrophages are viewed as immunosuppressive and involved in tissue repair and extracellular matrix remodeling [5,6]. However, alternatively activated macrophages may also contribute to disease processes in a complex way. For example, alternatively activated alveolar macrophages contribute to the fibrotic lesion in idiopathic pulmonary fibrosis [11] and in the liver fibrosis associated with *Schistosoma mansoni* [12].

Although classical and alternative activation are commonly viewed as the two opposing ends of macrophage activation, additional activation states may also exist [5,6]. For example, Anderson and Mosser [13] have described a third class of macrophages, called Type II macrophages. This state requires a specific two step activation pattern that involves ligation of Fc $\gamma$  receptors and signaling through Toll receptors, CD40 or CD44 [5,13,14]. The end result is decreased *IL-12* expression concomitant with increased *IL-10* mRNA. As a consequence, the gene profile of Type II macrophages is a mixture of pro-inflammatory and anti-inflammatory genes such as *IL-1*, *TNF- $\alpha$* , *IL-6*, *IL-*

*10* and *IL-4* [15]. Arginase, however, is not induced. A "deactivation" state of macrophages that is similar to Type II macrophages has also been described by Gordon [6].

Alzheimer's disease (AD) is characterized pathologically by extracellular fibrillar deposits in the parenchyma of the brain which are composed of the  $\beta$ -amyloid (A $\beta$ ) peptide 1-40 and 1-42 fragments of the amyloid precursor protein (APP) [16-18]. It is generally believed that soluble APP and various forms of A $\beta$  peptides, either alone or in conjunction with other immune factors, serve as activating signals for an innate immune response in the brain [19]. Using immunocytochemistry, Griffin et al [20] have demonstrated the presence of IL-1 $\beta$  in microglia and astrocytes surrounding the amyloid deposits. Other investigators have confirmed these findings and have also shown that IL-6, TNF $\alpha$  and MHC expression is increased in AD [21-25]. As a result, AD has been associated with classical immune activation and the production of an acute Th-1 immune response. However, AD is a chronic neurodegenerative disease in which the inflammatory process has not been thoroughly charted over time and with disease progression. It is highly likely that brain macrophages may change their activation state as a function of the disease and time. To assess this possibility, we have determined if genes associated with alternative activation are expressed in cortical samples from individuals with AD compared to cognitively normal aged matched control individuals. Additionally, we investigated the alternative activation-related gene expression profiles in mouse models of AD and of cerebral amyloid angiopathy. Our data demonstrate that genes typical of alternative activation are clearly expressed in AD and in a mouse model of amyloid deposition. However, it is likely that the macrophage activation state in AD represents a novel hybrid state between classical and alternative activation.

## Materials and methods

### Cell cultures and treatment conditions

BV2 microglia were used as a model of CNS murine microglia and have been extensively characterized [26]. For some experiments, primary murine microglia were also used and were prepared from mixed glial cultures from 2 day old postnatal pups in a standard fashion [27]. Cells from both cultures were maintained in 75 cm<sup>2</sup> flasks at 37°C in a 5% CO<sub>2</sub> humidified atmosphere in Dulbecco's Modified Eagle Medium (DMEM) with high glucose (4.5 g/L D-glucose, L-glutamine, pyridoxine HCl, and 110 mg/L sodium pyruvate; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin. For each experiment, cells were plated into 24 well dishes, after which the media was changed to the treatment media consisting of serum free DMEM with low glucose (1.0 g/L D-glucose, L-glutamine, pyridoxine HCl, and 110 mg/L sodium pyru-

vate; Invitrogen). Cells were then allowed to adapt to the serum-free media for 24 hours before starting the experiments. The stimulants used for the cell culture experiments included recombinant mouse IFN- $\gamma$  (100 U/ml, BioSource International Inc., Camarillo, CA, USA) and recombinant mouse IL-4 or IL-13 (20 ng/ml, BioSource International). Treatments were carried out in fresh serum-free media for 24 hours at 37°C in a 5% CO<sub>2</sub> humidified atmosphere, after which the assays were performed. All experiments were repeated a minimum of three times.

#### **Transgenic mice**

Transgenic mice (Tg-2576) containing the Swedish (K670N/M671L) APP double mutation were generously provided by Dr. Karen Hsiao-Ashe. Tg-SwDI mice containing the Swedish, and the CAA-associated Dutch (E22Q) and Iowa (D23N) APP mutations, were generated as described [28]. Tg-2576 mice, together with wild-type controls were maintained until 70 weeks of age. Tg-SwDI mice and their wild-type controls were maintained until 60 weeks of age and were of mixed gender. The mice were sacrificed and their brains were removed, snap-frozen in liquid nitrogen, and stored at -80°C. To isolate total RNA, cortical forebrain samples (approximately 100 mg) were homogenized in 1 ml of Trizol and extracted with 200  $\mu$ l of chloroform. The aqueous phase was separated by centrifugation (12,000  $\times$  g for 15 minutes at 4°C), mixed with an equal volume of 70% ethanol, and purified using the RNeasy mini-kit (QIAGEN Inc., Valencia, CA, USA). Synthesis of cDNA from the total RNA samples was performed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA).

#### **Human brain tissue**

Rapid autopsy human brain samples were obtained from Kathleen Price Bryan Brain Bank under Duke IRB approval. For this study, frozen frontal lobe (cortical) brain tissue samples were prepared from autopsy of individuals with pathologically confirmed AD and age-matched, cognitively normal control patients. Characteristics of the sample population are shown in Table 1. Average age and average post-mortem interval (PMI) were not significantly different between normal and AD populations. All normal individuals were diagnosed as Braak and Braak stage 1 while AD individuals were diagnosed as Braak and Braak stage IV or V. For each specimen, cortical gray matter was carefully dissected so as to minimize inclusion of white matter and subarachnoid blood vessels. Total RNA was isolated and converted to cDNA as described above.

#### **Real-time PCR**

Real-time PCR was performed using the TaqMan Gene Expression Assay Kit (Applied Biosystems) according to

the manufacturer's instructions. Briefly, cDNA samples (100 ng, based on the original RNA concentrations) were brought to a total volume of 22.5  $\mu$ l using RNase-free water and mixed with 25  $\mu$ l of 2X TaqMan Universal Master Mix (without AmpErase uracil-N-glycosylase) and 2.5  $\mu$ l of the respective 20X TaqMan Gene Expression Assay. Target amplification was performed in 96-well plates using a real-time sequence detection system instrument (ABI PRISM 9700HT, Applied Biosystems). The PCR thermal cycling conditions included an initial 10 minute hold at 95°C to activate the AmpliTaq Gold DNA polymerase, followed by 40 cycles of denaturation (15 seconds at 95°C) and annealing/primer extension (1 minute at 60°C). The data from the real-time PCR experiments were analyzed using the 2<sup>- $\Delta\Delta$ Ct</sup> method, which allows for the calculation of relative changes in gene expression [29]. For this method, the threshold cycle number (Ct) is normalized using a housekeeping gene (18s rRNA), calibrated to the control samples, and the result used as the exponent with a base of 2 to determine the fold change in gene expression. The treatment conditions used in this study did not alter the expression of 18s rRNA, thus validating its use as a normalizing factor. Untreated BV2 cells, littermate wild type mouse brains or non-AD, age matched human brain served as the comparator where appropriate. Primers for these experiments were purchased from Applied Biosystems Foster City, CA, USA. Table 2 provides the Applied Biosystems ID number for each gene and information on exact primer sequences is provided through the Applied Biosystems Web site [30].

#### **Statistical analyses**

The data were analyzed using GraphPad Software (PRISM) (San Diego, CA). One-way analysis of variance (ANOVA) was used to compare the means of the cell culture treatment groups. The data for the mouse (mutant versus wild-type) and human brain (AD versus control) samples were analyzed using either unpaired Student's t-test or the Wilcoxon Test, depending on whether the populations had equal variances as determined using the F-test.

#### **Results**

Alternative activation gene expression profiles have been described for tissue macrophages found in the periphery but have not been identified for brain macrophages, the microglia. Since induction of alternative activation has been linked to specific Th2 cytokines and in particular, to IL-4 and IL-13, we treated BV2 microglia with IL-4 (20 ng/ml) or IL-13 (20 ng/ml). We then used quantitative RT-PCR measurements to confirm the presence of specific genes known to be characteristic of alternative activation in IL-4/IL-13 treated cells compared to classically activated cells (treated with IFN $\gamma$ ) or untreated cells. As shown in Fig 1, BV2 cells demonstrate increased gene

**Table 1: AD and normal control brain – characteristics.**

	Age (yrs)	Gender	PMI (hrs)	Braak & Braak score	APOE 4 gene*
<b>Normal control</b>	78.3 ± 1.7 (29)	12 Male 17 Female	9.1 ± 1.6	Stage I	5(APOE 3/4)
<b>AD</b>	77.8 ± 1.0 (47)	23 Male 24 Female	6.8 ± 1.4	Stage 4–5	13 (APOE3/4) 14(APOE4/4)

\*Number of individuals expressing an APOE4 gene

expression for *AG1*, *MRC1*, *FIZZ* and *YM1* compared to untreated cells on induction by IL-4 or IL-13. In contrast, IFN $\gamma$  treatment did not induce any of the alternatively activated genes but did induce *TNF $\alpha$*  and *NOS2* mRNA, two well-described markers of classical activation. Co-treatment of IFN $\gamma$  with IL-4 reduced the expression of *MRC1*, *FIZZ* and *YM1* but not *AG1*, indicating that IFN $\gamma$  can generally oppose IL-4 action. A similar effect was observed for *TNF $\alpha$*  and *NOS2* mRNA where co-treatment with IL-4 plus IFN $\gamma$  opposed, in this case, IFN $\gamma$ -mediated induction. Primary microglia were also treated with either IL-4 or IFN $\gamma$  to confirm the findings in BV2 microglia. As shown in Fig 1F, IFN $\gamma$  induced an increased expression of


*NOS2* mRNA but did not affect either *AG1* or *MRC1* expression. In contrast, IL-4 treatment increased *AG1* and *MRC1* mRNA, suggesting that both BV2 microglia and primary microglia can demonstrate an alternative activation gene profile.

#### Alternative activation gene profiles in mouse models of AD

Since alternative activation could be demonstrated *in vitro* using the expression of specific genes, we determined if mouse models of amyloid deposition similar to AD exhibited an alternative activation gene profile. Two different transgenic mouse models were used, the APPsw Tg-2576 mouse containing the Swedish mutation [31,32]

**Table 2: Primer ID list. All primers were purchased from Applied Biosystems, Foster City, CA**

Mouse Primer/Probes		
Gene	origin	Applied Systems Batch ID
18s (Eukaryotic 18s rRNA)	ms	Hs99999901_s1
Arg1 (arginase 1, liver)	ms	Mm00475988_m1
Arg2 (arginase2, type II)	ms	Mm00477592_m1
Chi3l3 (chitinase 3-like 3, Ym1)	ms	Mm00657889_mH
IL1b (Interleukin 1 beta)	ms	Mm00434228_m1
Mrc1 (mannose receptor, C type 1)	ms	Mm00485148_m1
Nos2 (Nitric oxide synthase 2, inducible, macrophage)	ms	Mm00440485_m1
Ptprc (protein tyrosine phosphatase, receptor type, C, CD45)	ms	Mm00448463_m1
Retnl1 (resistin like alpha, FIZZ1)	ms	Mm00445109_m1
Slc7a2 (solute carrier family 7 (cationic amino acid transporter, y+system), member 2, Cat2)	ms	Mm00432032_m1
Slc7a3 (solute carrier family 7 (cationic amino acid transporter, y+system), member 3, Cat3)	ms	Mm00500256_m1
Tnf (tumor necrosis factor)	ms	Mm00443258_m1
Human Primer/Probes		
Name	origin	Batch ID
hARG1 (arginase, liver)	hu	Hs00163660_m1
hARG2 (arginase, type II)	hu	Hs00265750_m1
hCHI3L1 (chitinase 3-like 1 (cartilage glycoprotein-39))	hu	Hs00609691_m1
hCHI3L2 (chitinase 3-like 2)	hu	Hs00187790_m1
hIL1B (interleukin 1, beta)	hu	Hs00174097_m1
hMRC1 (mannose receptor, C type 1)	hu	Hs00267207_m1
hNOS2A (nitric oxide synthase 2A (inducible, hepatocytes))	hu	Hs00167248_m1
hPTPRC (protein tyrosine phosphatase, receptor type, C, hCD45)	hu	Hs00174541_m1
hSLC7A2 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 2, hCAT2)	hu	Hs00161809_m1
hSLC7A3 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 3, hCAT3)	hu	Hs00364157_m1
hTNF (tumor necrosis factor (TNF superfamily, member 2))	hu	Hs00174128_m1




**Figure 1**  
**Alternative activation genes are induced by treatment of microglia with IL-4 or IL-13.** BV2 cells were treated with IL-4 or IL-13 for 24 hrs and the mRNA expression levels for *AG1* (Panel A); *MRC1* (Panel B); *FIZZ* and *YM1* (Panel C) were determined using quantitative RT-PCR. mRNA levels for each of these genes significantly increased compared to untreated alone. IL-4 or IL-13 treatment failed to induce *TNFα* (Panel D) or *NOS2* (Panel E) mRNA expression. To determine if the alternative activation genes were induced by classical activation agents, cells were treated with IFNγ (panels A-C). In this case, no induction was observed with IFNγ treatment and, with the exception of *AG1* (A), treatment of BV2 cells with the combination of IFNγ and IL-4 reduced mRNA expression of each gene studied; Panel F- Primary microglia obtained from neonatal mouse cortex also demonstrated increased mRNA expression for alternative activation genes (*AG1*; *MRC1*) on stimulation with IL-4. *NOS2* was not increased by IL-4 treatment but was increased with IFNγ treatment. \* = p < 0.001 compared to IL-4 treated alone; \*\* = p < 0.001 compared to IFNγ treated alone; \*\*\* = p < 0.001 compared to untreated alone.

and the Tg-SwDI mouse model of cerebral amyloid angiopathy (CAA) [28,33]. Differences in the gene expression profiles between the mouse models were observed. In the Tg-2576 mouse (Fig 2A), among the alternative activation genes, *AG1*, *MRC1*, and *YM1* demonstrated significant increases in expression, while *FIZZ1* was expressed at wild-type levels. For genes commonly associated with classical activation, we found that *NOS2* mRNA was expressed at wild-type levels while *TNFα* mRNA expression was slightly, but significantly elevated (Fig. 2A). Cortical extracts from Tg-SwDI mice were also examined. Pathologically, these mice have predominantly cerebrovascular amyloid and have high levels of immune reactive microglia localized to the cerebral blood vessels [33,34]. In comparing the six genes in the Tg-SwDI CAA mouse model, we observed a significant increase only in *TNFα*

mRNA (Fig. 2B). The remaining genes failed to show a statistically significant difference between the mutant and wild-type animals.

**Brains from AD patients show increased gene expression of alternative activation markers**

To translate the data derived from cell culture and mouse models of AD, we measured expression levels of genes associated with classical and alternative activation in frontal lobe cortical extracts from AD patients and cognitively normal, age-matched controls individuals. As previously shown in Table 1, there were no significant differences between age or post-mortem interval (PMI) between groups. Messenger RNA expression levels were used rather than protein levels for detection of gene induction because RNA is typically less dependent on PMI than pro-

**Figure 2**


**Alternative activation genes in mouse models of amyloid pathology.** The transcripts of activation-related genes were measured in cortical extracts from Tg-2576 (AD model) and Tg-SwDI mice (CAA model) using quantitative RT-PCR. The data are presented as the average ( $\pm$  SEM) fraction of control levels where the appropriate aged-matched wild type littermate mice served as the comparator control. **A. Tg-2576 mice-** mRNA for *TNF $\alpha$*  ( $p < 0.01$ ), *AGI* ( $p = 0.05$ ), *MRC1* ( $p < 0.01$ ), and *YM1* ( $p < 0.02$ ) were significantly increased in the Tg-2576 mice brain. **B. Tg-SwDI mice-** Only *TNF $\alpha$*  mRNA levels were significantly increased ( $p < 0.05$ ) in Tg-SwDI mouse brain.

tein stability [35]. In addition, partial degradation of RNAs that may occur in post-mortem tissue does not obscure the reliable detection of specific mRNA transcripts using RT-PCR [35]. For the genes identified in classical activation, we found that *NOS2* mRNA expression and *IL-1 $\beta$*  mRNA expression were not significantly different between control and AD, while *TNF $\alpha$*  mRNA was significantly increased in the AD group (Fig. 3). Among the alternative activation genes, we found that *AGI* mRNA was increased approximately 2 fold in AD while *MRC1* mRNA increased slightly but did not attain statistical significance due to a large variation in values. We were unable to detect expression of human *FIZZ1* in any of the AD or control brain tissue samples. The remaining alternative activation gene, *YM1* (also known as chitinase 3-like 3), has no direct human homologue. Thus, we selected two human genes closely related to *YM1*, that is; chitinase 3-like 1 (*CHI3L1*) and chitinase 3-like 2 (*CHI3L2*) [36]. We found that both *CHI3L1* and *CHI3L2* mRNAs were expressed at approximately 3 fold higher in AD brain compared to age matched controls. As an additional control, we also measured the expression of arginase 2 (*AG2*) mRNA, which encodes a mitochondrial isoform of arginase that is expressed in macrophages, neurons and astrocytes, but is not as commonly associated with immunological regulation as is *AGI* [37]. *AG2* was expressed at equivalent levels between the AD and control

samples, suggesting that the increase in *AGI* mRNA was unlikely to be non-specific. Microglial and macrophage cell number were compared between control and AD tissue by measuring the expression of *CD45*, which is expressed on both resting and activated microglia [38,39]. In contrast to rodent brain [39], *CD45* expression level is independent of activation state in human microglia [40]. Our data show that *CD45* mRNA was expressed at equivalent levels between the AD and control groups and suggests that the numbers of microglia are grossly the same. A similar result was found for *CAT3*, a neuronal arginine transporter while cationic amino acid transporter 2 (*CAT2*), an immune inducible arginine transporter found in microglia, astrocytes and neurons [41], was also significantly increased in AD.

## Discussion

The regulation of gene transcription in macrophages during immune activation is dependent on multiple factors including the type of phagocytic ligands, the types of non-phagocytic adhesion interactions, the extracellular matrix and the cytokine environment [6,42]. Multiple, distinct populations of macrophages have been identified and include classically activated macrophages that are pro-inflammatory and associated with the "killing" phase of the innate immune response and alternatively activated macrophages that are primarily associated with wound



**Figure 3**

**Alternative activation genes in Alzheimer's disease.** mRNA expression was determined for *NOS2*, *TNF $\alpha$* , *IL-1 $\beta$* , *AG1*, *MRC1*, *CHI3L1*, *CHI3L2*, *AG2*, *CD45*, *CAT 2* and *CAT3* in frontal lobe cortical extracts from AD patients and age-matched, cognitively normal controls. The real-time PCR results are expressed as the average ( $\pm$  SEM) fraction of control where age-matched, cognitively normal brain served as the comparator control. The data show significant elevations in mRNA expression levels for *AG1* (\* =  $p < 0.04$ ), *CHI3L1* (\*\* =  $p < 0.006$ ), and *CHI3L2* (\* =  $p < 0.04$ ). *NOS2* and *IL-1 $\beta$*  mRNA did not change but *TNF $\alpha$*  mRNA increased significantly (\* =  $p < 0.04$ ) in AD. *CAT2* mRNA, which encodes the inducible arginine transporter, also significantly increased (# =  $p < 0.02$ ) in AD compared to control. *AG2*, *MRC1*, *CD45* and *CAT3* mRNA expression levels were equivalent between the AD and control brains.

healing and tissue repair. Type II macrophages that appear to be a hybrid activation state share some characteristics of each [5,6]. Peripheral macrophages cycle between these activation states, and dysregulation of this cycling underlies various forms of chronic disease [43].

To determine if innate immune cells of the brain exhibit alternative activation, we have used quantitative RT-PCR to identify a specific gene profile. This profile was created by stimulating BV2 and primary murine microglia with anti-inflammatory cytokines used to induce an alternative activation state in peripheral macrophages. Similar to

peripheral macrophages, microglia treated with IL-4 or IL-13 significantly increased mRNA expression levels for *AG1*, *MRC1*, *FIZZ* and *YM1*, alternative activation genes. In contrast, genes for classical activation, *NOS2* and *TNF $\alpha$* , were not increased by either IL-4 or IL-13 treatment. Thus, our data confirm previously published studies on peripheral murine macrophages and provide a tool to assess the presence of alternative activation gene induction in the brain.

Using this gene expression pattern, we then probed cortical tissue from two transgenic mouse models of AD and

from individuals with AD for evidence of alternative activation genes. These results are compared in Table 3. Essentially, cortical tissue from the Tg-2576 mouse and individuals with AD demonstrate a mixed profile of alternative activation and classical activation genes, particularly  $TNF\alpha$ . The Tg-SwDI mouse that represents a cerebrovascular amyloid model, however, primarily demonstrates classical activation.

The presence of alternative activation genes in AD necessitates a more complex view of inflammation in neurodegenerative disease. Numerous studies have shown that the immune cells in the vicinity of amyloid deposits in AD express mRNA and proteins for pro-inflammatory cytokines, leading to the hypothesis that AD is primarily associated with classical (Th-1) immune activation [20,44-47]. Multiplex ribonuclease protection assays and gene micro-array studies have only partially confirmed this hypothesis [46,48,49]. For example, Blalock et al [48] have examined gene profiles found in AD using gene arrays on brain samples from 22 AD subjects. The primary pro-inflammatory genes represented were MHC class II and  $IFN\gamma$ , although IL-18 mRNA expression was elevated as well as genes for cytokine receptors, particularly IL-6R and IL-10R. A second array analysis by Xu et al [49] confirmed the increased in MHC class II but did not find changes in other pro-inflammatory genes. Coangelo et al [25], however, found a 3-fold increase in IL-1 $\beta$  expression using a DNA microarray analysis based on pooled AD brain samples compared to pooled control samples. The discrepancies and variability in gene expression patterns between the published studies are puzzling, especially in view of the fact that acute exposure of microglia to A $\beta$  peptides initiates a classical activation pattern of gene expression [23,50-52]. There are many possible reasons for the differences between the *in vitro* and *in vivo* data. Hoozemans et al [53] have suggested that the sequence and timing of pathological events in AD is critical. We further suggest that microglia may exhibit specific stages of response during a chronic neuroinflammatory disease such as AD. These stages in microglia in AD may be simi-

lar to those stages observed in chronic inflammatory diseases of the lung or liver, including the induction of alternative activation.

A shift to alternative activation in brain innate immune cells is supported by the analysis of mRNA expression for classical and alternative genes in the Tg-2576 mouse model of AD, a well-studied animal model for CNS parenchymal amyloid deposition [32]. *AGI*, *MRC 1* and *YMI* mRNA levels were significantly increased in the Tg-2576 mouse brains compared to age-matched controls while *TNF $\alpha$*  and *NOS2*, genes commonly associated with classical activation, increased and did not change, respectively. The increased *TNF $\alpha$*  mRNA suggests a mixed activation state reminiscent of Type II macrophage activation [5]. However, both classical and Type II activated peripheral macrophages exhibit increased *NOS2* mRNA, not decreased *NOS2*, and no induction of *AGI*. Thus, since *NOS2* mRNA induction is not observed in peripheral macrophages that exhibit alternative activation, while *AGI* expression is increased [5,54,55], the preponderance of the data suggest that alternative activation is a dominant feature of the innate immune response in the APP Tg-2576 mouse. However, we cannot rule out that activation state in the APP Tg-2576 mouse is a novel, hybrid state.

In contrast, the Tg-SwDI mouse model, which represents a localized cerebrovascular amyloid angiopathy [33,34], did not demonstrate the same increase in alternative activation markers. These differences may be due to the predominant cerebrovascular microglial proinflammatory phenotype that is observed in Tg-SwDI mice brains or in humans who express either the Iowa or Dutch mutation [33,56]. An increase in *TNF $\alpha$*  mRNA observed in the Tg-SwDI mice brains is consistent with this hypothesis.

Both classical and alternative activation markers were also observed in brains from AD patients and resemble the activation pattern found in Tg-2576 mice. In AD brain, mRNAs for *TNF $\alpha$* , *AGI*, *CHI3L1* and *CHI3L2* were significantly increased in cortical samples compared to age-matched control brains while no significant difference was observed for *MRC1* mRNA. The strong presence of the alternative activation genes in cortical tissue samples in AD brain implies that cells, such as microglia or astrocytes, have undergone a shift in functional profile. This finding does not negate immunocytochemical studies that demonstrate discretely localized, pro-inflammatory cytokine expression such as IL-1 $\beta$  in plaque associated microglia or astrocytes. However, the presence of alternative activation markers in plaque associated cells has not been determined. Thus, it is not clear if microglia within the vicinity of plaques show a complex activation state or if some cells express pro-inflammatory genes while others

**Table 3: Comparison of alternative activation gene profile.**

	<b>Tg-2756</b>	<b>Tg-SwDI</b>	<b>AD</b>
<b><i>TNF<math>\alpha</math></i></b>	Increased	Increased	Increased
<b><i>NOS2</i></b>	No Change	No Change	No Change
<b><i>AGI</i></b>	Increased	No Change	Increased
<b><i>CHI3L1</i></b>	-	-	Increased
<b><i>CHI3L2</i></b>	-	-	Increased
<b><i>YMI</i>*</b>	Increased	No Change	-
<b><i>FIZZI</i>**</b>	No Change	No Change	-
<b><i>MRC1</i></b>	Increased	No Change	No Change

\* Rodent only- shares homology with CHI3-family

\*\* Rodent only-shares homology with Resistin family

express alternative activation genes in a mosaic-like pattern.

The induction signal(s) for alternative activation in the amyloid mouse models and in AD remains unclear. Although IL-4 and IL-13 have been most closely linked to alternative activation [6], other Th-2 cytokines such as IL-10 and TGF $\beta$  down-regulate inflammation and are involved in repair and matrix remodeling [6,57-59]. Of these, only TGF $\beta$  has been firmly observed in AD brain [60,61]. While both TGF $\beta$  and IL-10 immunoreactivity have been detected in brains of Tg-2576 mouse [45]. The effects of anti-inflammatory cytokines in AD are largely unknown. Recently, however, Koenigsnecht-Talboo and Landreth [62] have shown that IL-4, IL-13, TGF $\beta$  or IL-10 enhance uptake of fibrillar A $\beta$  peptides. Interestingly, no effect on A $\beta$  uptake is observed with the anti-inflammatory cytokines alone, but instead, they serve to reduce the suppression of A $\beta$  phagocytosis initiated by pro-inflammatory cytokines. These findings underscore the complexity of the brain's cytokine environment and its role in modifying microglial responses to A $\beta$  peptides. A $\beta$ , itself, may also influence the gene switch from classical towards alternative activation in microglia. Fibrillar A $\beta$  interacts with numerous microglial membrane receptors including scavenger receptors A and B; CD40; an  $\alpha$ 6/ $\beta$ 1 integrin/CD36/CD47 complex and complement receptors [63-67]. Crosslinking of these or other receptors has been associated with macrophage "down-regulation" through multiple mechanisms [68,69]. For example, mannose receptor signaling initiates an anti-inflammatory program within macrophages [68]. MRC-1 (CD206) is a transmembrane glycoprotein that mediates Ca<sup>2+</sup> dependent endocytosis and phagocytosis of mannoseylated ligands [58] whose role in AD is currently unknown.

The induction of alternative activation genes is commonly considered to be a harbinger of repair and extracellular matrix re-organization that may begin during or after the first stages of an acute innate immune response [6,70,71]. Although the exact functions of many of the protein products of these genes are not clear, some alternative activation genes such as *AG1* have been well studied in peripheral macrophages. Both isoforms of arginase utilize arginine as a substrate for biosynthetic pathways that produce polyamines and proline [72]. Polyamines such as spermine are well known to alter cell proliferation but have wide-ranging physiological effects such as regulation of NMDA channel function, membrane potentials and gene transcription [73,74]. Proline is an important component of collagens and is involved in repair of the extracellular matrix. The maintenance of high *AG1* expression, as observed in our studies, is likely to direct arginine utilization toward the production of proline or polyamines and away from the production of nitric oxide. The enzymatic

activities of both inducible NOS and arginase are solely dependent on intracellular arginine and these enzymes compete for arginine [72]. The low expression of *NOS2* mRNA coupled with the increased expression of *CAT2* mRNA, a critical arginine transporter, observed in our AD samples may further promote arginase activity. Interestingly, Hesse et al [12,54]. have shown that increased *AG1* expression in schistosome egg-induced granulomas is associated with increased proline and polyamine production and promotes fibrosis in liver. Hesse et al [54] demonstrated that the re-induction of *NOS2* expression or activity reduced the fibrotic load in the parasite-induced liver granulomatosis model. The upregulation of *AG1* in AD, coupled with the loss of *NOS2* mRNA, then, may have critical relevance to amyloid deposition in the extracellular matrix of the brain.

The *FIZZ1* and *YM1* genes also provide a link between alternatively activated macrophages and repair processes after infection or injury [10,70]. The protein product of *YM1* induction is a novel mammalian lectin that binds saccharides and heparin/heparin sulfate on cell surfaces, but whose functions are largely unknown [70,75]. Hung et al [75] have suggested that *YM1* helps to protect the extracellular matrix scaffold at sites of injury by reducing heparin sulfate degradation. *FIZZ1* encodes a 9.4 kDa cysteine rich protein which was originally described in lung lavage fluids in a murine allergic pulmonary inflammation model [11]. Three *FIZZ* family members have been identified and are now known to be part of a new gene family of resistin-like molecules. As such, *FIZZ* proteins may contribute to insulin resistance during diabetes but they have also been linked to angiogenesis, to stimulation of collagen production and to inhibition of apoptosis [10,11,76]. Although a human homolog exists for *FIZZ1*, no direct human homologs have been identified for *YM1*. Our data, however, demonstrates that two closely related chitinase genes, namely *CHI3L1* and *CHI3L2* are overexpressed in AD brain. Both forms of chitinase 3-like proteins do not have enzymatic chitinase activity and instead, inhibit IL-1 and TNF $\alpha$ -mediated responses by blocking cell signaling [8].

In summary, immune cells within the brain display gene profiles that suggest heterogeneous, functional phenotypes that range from a pro-inflammatory, classical activation state to an alternative activation state involved in repair and extracellular matrix remodeling. These different functional phenotypes not only protect the tissue from invaders, but orchestrate and promote tissue reconstruction resulting in resolution of the injury. Repair processes mediated by alternative activation genes, however, can be associated with maintenance of disease and, in particular, enhanced fibrosis [6,12,77]. For example, diseases in the periphery that have fibrosis as a characteristic fea-

ture, such as *Schistosoma japonicum* egg induced fibrosis in the lung, *Schistosoma mansoni* infection of the liver or idiopathic lung fibrosis show defective repair that, in fact, favors fibrosis [54,55,77]. Anti-inflammatory cytokine treatment under these circumstances worsens the fibrosis, while the re-establishment of NOS induction and activity reduces the fibrosis [12,77]. Neuroinflammation in AD is characterized by both degeneration and regeneration that occurs in a specific pattern of time and locale [53]. Studies on AD neuropathology implicate the presence of a defective repair process that is linked to the presence of Abeta peptides and amyloid fibrils [[53];78]. Our data presented here begin to build the case that alternative activated macrophages are present in AD brain and may contribute to a Th-2-linked, rather than a Th-1 linked, pathology. If true, then therapeutic approaches may need to consider this additional alteration of the immune response.

### Competing interests

The author(s) declare that they have no competing interests.

**Other Competing interests (not pertinent to the manuscript):** MPV is a principal in Cognosci, Inc.

### Authors' contributions

CAC designed the study, analyzed data, prepared figures and wrote the manuscript. RM performed Q RT-PCR experiments, analyzed data and contributed to the preparation of the manuscript; HS performed Q RT-PCR; QX prepared brain samples, performed Q RT-PCR and analyzed data; WVN provided transgenic mice and contributed to the preparation of the manuscript; MPV provided transgenic mice, participated in the study design and in the manuscript preparation.

### Acknowledgements

The authors would like to thank Dr. Christine M. Hulette and John Ervin, from the Kathleen Byran Brain Bank for AD and normal control brain tissue. This work was supported by NIH grants NS 36718, AG 19780, NS36645 and NS 043954.

### References

- Hume D: **The mononuclear phagocyte system revisited.** *J Leukocyte Biol* 2004, **72**:621-627.
- Nguyen M, Julien J, Rivest S: **Innate immunity: The missing link in neuroprotection and neurodegeneration.** *Nat Rev Neurosci* 2002, **3**:216-226.
- Adams D, Hamilton T: **The cell biology of macrophage activation.** *Ann Rev Immunol* 1984, **2**:283-318.
- Adams D: **Regulation of macrophage function by interferon- $\gamma$ .** In *Interferon* Edited by: Baron S, Coppenhaver D, Dianzani F, Fleischmann, W, Hughes T, Klimpel G, Niesel D, Stanton G, Tyring S. Galveston, TX: University of Texas Medical Branch; 1992:341-351.
- Mosser D: **The many faces of macrophage activation.** *J Leukocyte Biol* 2003, **73**:209-212.
- Gordon S: **Alternative activation of macrophages.** *Nat Rev Immunol* 2003, **3**:23-35.
- Stein M, Keshaw S, Harris N, Gordon S: **Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.** *J Exp Med* 1992, **176**:287-292.
- Ling H, Recklies A: **The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular response to the inflammatory cytokines interleukin-1 and tumor necrosis factor alpha.** *Biochem J* 2004, **380**:651-659.
- Nair MG, Cochrane D, Allen J: **Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro.** *Immunol Lett* 2003, **85**:173-180.
- Chang N, Hung S, Hwa K, Kato I, Chen J, Liu C, Chang AC: **A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin.** *J Biol Chem* 2001, **276**:17497-17506.
- Holcomb IN, Kanakoff R, Chan B, Baker T, Gurney A, Henzel W, Nelson C, Lowman H, Wright B, Skeleton N, Frantz D, Tumas D, Peale F, Shelton D, Hebert C: **FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family.** *EMBO J* 2000, **19**:4046-4055.
- Hesse M, Modolell M, La Flamme A, Schito M, Fuentes J, Cheever A, Pearce E, Wynn T: **Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.** *J Immunol* 2001, **167**:6533-6544.
- Anderson D, Mosser D: **A novel phenotype for an activated macrophage: the type 2 activated macrophage.** *J Leukocyte Biol* 2002, **72**:101-106.
- Gerber J, Mosser D: **Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors.** *J Immunol* 2001, **166**:6861-6868.
- Rodriguez N, Chang H, Wilson M: **Novel program of macrophage gene expression induced by phagocytosis of *Leishmania chagasi*.** *Infect Immun* 2004, **72**:2111-2122.
- Selkoe D, Schenk D: **Alzheimer's disease: Molecular understanding predicts amyloid based therapeutics.** *Annu Rev Pharmacol Toxicol* 2003, **43**:545-584.
- Hardy J, Selkoe D: **The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.** *Science* 2002, **297**:353-356.
- Glennier G, Wong C: **Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein.** *Biochem Biophys Res Commun* 1984, **120**:885-890.
- Mrak R, Griffin WS: **Glia and their cytokines in progression of neurodegeneration.** *Neurobiol Aging* 2005, **26**:349-354.
- Griffin WST, Stanley L, Ling C, White L, MacLeod V, Perrot L, White CL 3rd, Araoz C: **Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.** *Proc Natl Acad Sci* 1989, **86**:7611-7615.
- Akiyama H: **Inflammatory response in Alzheimer's disease.** *Tohoku J Exp Med* 1994, **174**:295-303.
- Eikelenboom P, Rosemuller JM, Van Muiswinkel F: **Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression.** *Exp Neurol* 1998, **154**:89-98.
- Klegeris A, Walker D, McGeer P: **Activation of macrophages by Alzheimer beta amyloid peptide.** *Biochem Biophys Res Commun* 1994, **199**:984-991.
- McGeer P, Itagaki S, Tago H, McGeer E: **Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.** *Neurosci Lett* 1987, **79**:195-200.
- Coangelo V, Schurr J, Ball M, Pelaez R, Bazan N, Lukiw W: **Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling.** *J Neurosci Res* 2002, **70**:462-473.
- Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F: **Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus.** *J Neuroimmunol* 1990, **27**:229-237.
- Colton C, Snell J, Cherynshev O, Gilbert D: **Induction of superoxide anion and nitric oxide production in cultured microglia.** In *The Neurobiology of NO and OH* Edited by: Chieuh C, Gilbert D, Colton C. New York: Annals of the New York Academy of Sciences; 1994:54-63.
- Davis J, Xu F, Deane R, Romanov G, Previti M, Zeigler K, Zlokovic B, Van Nostrand W: **Early-onset and robust cerebral microvascu-**

- lar accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Lowa mutant form of amyloid beta-protein precursor. *J Biol Chem* 2004, **279**:20296-20306.
29. Livak KJ, Schmittgen T: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.** *Methods* 2001, **25**:402-408.
  30. **Applied Biosystems Web Site** [<http://www.appliedbiosystems.com>]
  31. Irizarry M, McNamara M, Fedorchak K, Hsiao K, Hyman B: **APPsw transgenic mice develop age related A $\beta$  deposits and neuropil abnormalities but no neuronal loss in CA1.** *J Neuropathol Exp Neurol* 1997, **56**:965-97.
  32. Hsiao K, Chapman P, Nilssen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: **Correlative memory deficits, A $\beta$  elevation and amyloid plaques in transgenic mice.** *Science* 1996, **274**:99-102.
  33. Miao J, Xu F, Davis J, Otte-Holler I, Verbeek M, Van Nostrand WE: **Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein.** *Am J Pathol* 2005, **167**:505-515.
  34. Miao J, Vitek M, Xu F, Previti M, Davis J, Van Nostrand W: **Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice.** *J Neurosci* 2005, **25**:6271-6277.
  35. Hynd M, Lewohl J, Scott H, Dodd P: **Biochemical and molecular studies using human autopsy brain tissue.** *J Neurochem* 2003, **85**:543-562.
  36. Hu B, Trinh K, Figueira W, Price P: **Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family.** *J Biol Chem* 1996, **271**:19415-19420.
  37. Louis C, Mody V, Henry W, Reichner J: **Regulation of arginase isoforms I and II by I-4 in cultured murine peritoneal macrophages.** *Am J Physiol* 1999, **276**:R237-242.
  38. Karp H, Tillotson M, Soria J, Reich C, Wood J: **Microglial tyrosine phosphorylation systems in normal and degenerating brain.** *Glia* 1994, **11**:284-290.
  39. Mittlebronn M, Dietz K, Schluesener H, Meyermann R: **Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude.** *Acta Neuropathol (Berl)* 2006, **101**:249-255.
  40. Becher B, Antel JP: **Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia.** *Glia* 1996, **18**:1-10.
  41. Bae S, Xu Q, Hutchinson D, Colton CA: **Y+ and y+ L arginine transporters in neuronal cells expressing tyrosine hydroxylase.** *Biochim Biophys Acta* 2005, **1745**:65-73.
  42. Misson P, vandenBrule S, Barbarin V, Lison D, Huaux F: **Markers of macrophage differentiation in experimental silicosis.** *J Leuko Biol* 2004, **76**:926-932.
  43. McGrath M, Kodolja V: **Balanced macrophage activation hypothesis: a biological model for development of drugs targeted at macrophage functional states.** *Pathobiology* 1999, **67**:277-281.
  44. Benzing W, Wujek J, Ward E, Shaffer D, Ashe K, Younkin S, Brunden K: **Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice.** *Neurobiol Aging* 1999, **20**:581-589.
  45. Apelt J, Schliebs R:  **$\beta$ -amyloid-induced glial expression of both pro and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology.** *Brain Res* 2001, **894**:21-30.
  46. Mehlhorn G, Holborn M, Schliebs R: **Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology.** *Int J Dev Neurosci* 2000, **18**:423-431.
  47. Abbas N, Bednar I, Mix E, Maire S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J: **Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice.** *J Neuroimmunol* 2002, **126**:50-57.
  48. Blalock E, Geddes J, Chen K, Porter M, Markesbery W, Landfield P: **Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses.** *Proc Natl Acad Sci USA* 2004, **101**:2173-2178.
  49. Xu P, Li Y, Qin X, Scherzer C, Xu H, Schmechel D, Hulette C, Ervin J, Gullans S, Haines J, Pericak-Vance M, Gilbert J: **Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease.** *Neurobiol Dis* 2006, **21**:256-275.
  50. Meda L, Cassatella M, Szendrel G, Otvos L, Baron P, Villalba M, Ferrari D, Rossi F: **Activation of microglial cells by  $\beta$ -amyloid protein and interferon- $\gamma$ .** *Nature* 1995, **374**:647-650.
  51. Rogers J, Cooper N, Webster S, Schultz J, McGeer P, Styren S, Civin H, Brachova L, Bradt B, Ward P, Lieberburg I: **Complement activation by  $\beta$ -amyloid in Alzheimer's disease.** *Proc Natl Acad Sci* 1992, **89**:10016-10020.
  52. Walker D, Link J, Lue L, Dalsing-Hernandez J, Boyes B: **Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes.** *J Leukoc Biol* 2006, **79**:596-610.
  53. Hoozemans JJ, Veerhuis R, Rozemuller J, Eikelenboom P: **Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.** *Int J Dev Neurosci* 2006, **24**:157-165.
  54. Hesse M, Cheever A, Jankovic D, Wynn T: **NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease.** *Am J Pathol* 2000, **157**:945-955.
  55. Davila H, Magee T, Vernet D, Rajifer J, Gonzalez-Cadavid N: **Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease.** *Biol Reprod* 2004, **71**:1568-1577.
  56. Maat-Schieman M, Yamaguchi H, Hegeman-Kleinn I, Schultz J, McGeer P, Styren S, Civin H, Brachova L, Bradt B, Ward P, Lieberburg I: **Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type.** *Acta Neuropathol (Berl)* 2004, **107**:389-398.
  57. Noel W, Raes G, Hassanzadeh G, DeBaetselier P, Beschin A: **Alternatively activated macrophages during parasitic infections.** *Trends Parasitol* 2004, **20**:126-133.
  58. Taylor P, Martinez-Pomares L, Stacey M, Lin HH, Brown G, Gordon S: **Macrophage receptors and immune recognition.** *Annu Rev Immunol* 2005, **23**:901-944.
  59. El-Gayar S, Thuring-Nahler H, Pfeilschifter J, Rollinghoff M, Bogdan DC: **Translational control of inducible nitric oxide synthase by IL13 and arginine availability in inflammatory macrophages.** *J Immunol* 2003, **171**:4561-4568.
  60. Wang G, Zhang Y, Chen B, Cheng J: **Preliminary studies on Alzheimer's disease using cDNA microarrays.** *Mech Ageing Dev* 2003, **124**:115-124.
  61. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P: **Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.** *Neurol Sci* 2006, **27**:33-39.
  62. Koenigsnecht Talboo J, Landreth G: **Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines.** *J Neurosci* 2005, **25**:8240-8249.
  63. Calingasan N, Erdely H, Altar C: **Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury.** *Neurobiol Aging* 2002, **23**:31-39.
  64. Townsend K, Town T, Mori M, Lue L, Shytle D, Sanberg P, Morgan D, Fernandez F, Flavell R, Tan J: **CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide.** *Eur J Immunol* 2005, **35**:901-910.
  65. El Khoury J, Hickman S, Thomas C, Cao L: **Scavenger receptor-mediated adhesion of microglia to beta amyloid fibrils.** *Nature* 1996, **382**:716-719.
  66. Bamberger M, Harris M, McDonald D, Husemann J, Landreth G: **A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.** *J Neurosci* 2003, **23**:2665-2674.
  67. Ricciarelli R, D'Abramo C, Zingg J, Giliberto L, Markesbery W, Azzi A, Marinari U, Pronzato M, Tabaton M: **CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease.** *Free Radic Biol Med* 2004, **36**:1018-1024.
  68. Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G, Monti P, Piemonti L, Biondi A, Mantovani A, Introna M, Allavena P: **Cross-linking of the mannose receptor on monocyte derived**

- dendritic cells activates an anti-inflammatory immunosuppressive program. *J Immunol* 2003, **171**:4552-4560.
69. Koenigsknecht J, Landreth G: **Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism.** *J Neurosci* 2004, **24**:9838-9846.
  70. Raes G, Noel W, Beschin A, Byrs L, DeBaetselier P, Hassanzadeh GH: **FIZZ1 and Ym as tools to discriminate between differentially activated macrophages.** *Dev Immunol* 2002, **9**:151-159.
  71. Wu G, Morris SM Jr: **Arginine metabolism: nitric oxide and beyond.** *Biochem J* 1998, **336**:1-17.
  72. Williams K: **Interactions of polyamines with ion channels.** *Biochem J* 1997, **325**:289-297.
  73. Thomas T, Thomas TJ: **Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications.** *Cell Mol Life Sci* 2001, **58**:244-258.
  74. Hung S, Chang A, Kato I, Chang N: **Transient expression of Ym I, a heparin-binding lectin, during developmental hematopoiesis and inflammation.** *J Leukoc Biol* 2002, **72**:72-82.
  75. Stutz A, Pickart L, Trigilieff A, Baumruker T, Preischl-Strassmayr E, Woisetschlager M: **The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism.** *J Immunol* 2003, **170**:1789-1796.
  76. Sandler N, Mentink-Kane M, Cheever A, Wynn T: **Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair.** *J Immunol* 2003, **171**:3655-3667.
  77. Eikelenboom P, VanGool W: **Neuroinflammatory perspectives on the two faces of Alzheimer's disease.** *J Neural Transm* 2004, **111**:281-294.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

